ClinicalTrials.gov
public full text
Public Domain
Advanced Refractory Solid Tumors With TP53 Mutations Register Study
The efficacy and safety of the PARP inhibitor in combination with the VEGFR inhibitor will be investigated in advanced refractory solid tumors patients with TP53 mutation .
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors#1321550
- Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors#1140178
- Endostatin in Treating Patients With Advanced Refractory Solid Tumors#873296
- A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation#1045159
- DOTr/DOTa Algorithm Guidance for Refractory Solid Tumors#1164487
Record · ID 1370335
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive